NeurAxis, Inc. (NRXS)

NYSEAMERICAN: NRXS · IEX Real-Time Price · USD
2.970
-0.030 (-1.00%)
Jun 14, 2024, 3:59 PM EDT - Market closed
-1.00%
Market Cap 19.74M
Revenue (ttm) 2.30M
Net Income (ttm) -14.57M
Shares Out 6.65M
EPS (ttm) -3.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,358
Open 2.940
Previous Close 3.000
Day's Range 2.920 - 3.000
52-Week Range 1.800 - 6.930
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date May 22, 2024

About NRXS

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and cha... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 9, 2023
Employees 19
Stock Exchange NYSEAMERICAN
Ticker Symbol NRXS
Full Company Profile

Financial Performance

In 2023, NeurAxis's revenue was $2.46 million, a decrease of -8.37% compared to the previous year's $2.68 million. Losses were -$14.63 million, 206.0% more than in 2022.

Financial Statements

News

NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with NYSE Guidelines on Audit Disclosure

CARMEL, Ind., June 07, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing c...

7 days ago - GlobeNewsWire

NeurAxis Reports First Quarter 2024 Financial Results

CARMEL, Ind., May 22, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic a...

23 days ago - GlobeNewsWire

NeurAxis to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

CARMEL, Ind., May 21, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ch...

24 days ago - GlobeNewsWire

NeurAxis to Host First Quarter 2024 Results and Business Update Call on Wednesday, May 22, 2024

CARMEL, Ind., May 15, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ch...

4 weeks ago - GlobeNewsWire

NeurAxis Announces New Medical Policy Coverage in North Dakota

CARMEL, Ind., April 23, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...

7 weeks ago - GlobeNewsWire

NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

CARMEL, Ind., April 09, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic...

2 months ago - GlobeNewsWire

NeurAxis to Host Fourth Quarter and Full Year 2023 Results and Business Update Call on Tuesday, April 9, 2024

CARMEL, Ind., April 01, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...

2 months ago - GlobeNewsWire

NeurAxis Announces IB-Stim Results from a Large, Pediatric, Multi-Center Registry

CARMEL, Ind., March 27, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...

2 months ago - GlobeNewsWire

NeurAxis Announces Highmark BCBS Policy Coverage

CARMEL, Ind., March 11, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...

3 months ago - GlobeNewsWire

NeurAxis Announces Blue Cross and Blue Shield of Kansas City Policy Coverage

CARMEL, Ind., March 04, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...

3 months ago - GlobeNewsWire

NeurAxis to Present at Oppenheimer 34th Annual Healthcare MedTech & Services Conference

CARMEL, Ind., Feb. 27, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that addres...

3 months ago - GlobeNewsWire

NeurAxis Appoints Timothy Henrichs as Chief Financial Officer

CARMEL, Ind., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address ...

4 months ago - GlobeNewsWire

NeurAxis, Inc. Issues Letter to Shareholders from Brian Carrico, President and Chief Executive Officer

CARMEL, Ind., Dec. 20, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address ...

6 months ago - GlobeNewsWire

NeurAxis Reports Third Quarter 2023 Financial Results

CARMEL, Ind., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address ...

7 months ago - GlobeNewsWire

NeurAxis Announces CareFirst BCBS Policy Coverage

CARMEL, Ind., Nov. 15, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing c...

7 months ago - GlobeNewsWire

NeurAxis Secures $3 Million Financing

CARMEL, Ind., Nov. 14, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing c...

7 months ago - GlobeNewsWire

NeurAxis Signs Exclusive Option Agreement with University of Michigan for Innovative Gastrointestinal Device

CARMEL, Ind., Nov. 08, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing c...

7 months ago - GlobeNewsWire

NeurAxis Reports Second Quarter 2023 Financial Results

CARMEL, Ind., Sept. 21, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address...

9 months ago - GlobeNewsWire

NeurAxis to Present at the Gilmartin Group Emerging Growth Showcase

CARMEL, Ind., Sept. 13, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that addre...

9 months ago - GlobeNewsWire

NeurAxis Announces Publication of Prospective Study Showing IB-Stim™ Improves Quality of Life of Adolescents with IBS

CARMEL, Ind., Sept. 12, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that addres...

9 months ago - GlobeNewsWire

NeurAxis Highlights Pediatric Post-Concussion Clinical Study

CARMEL, Ind., Aug. 29, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that address...

10 months ago - GlobeNewsWire

NeurAxis Highlights Strength of its Board of Directors

CARMEL, Ind., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that addres...

10 months ago - GlobeNewsWire

NeurAxis Highlights Two Independent Studies Showing Benefits of IB-Stim in Adolescents Involving the Gut Microbiome

CARMEL, Ind., Aug. 22, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that addres...

10 months ago - GlobeNewsWire

NeurAxis Announces Over $8 Million in IB-Stim™ Revenue

CARMEL, Ind., Aug. 17, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address ...

10 months ago - GlobeNewsWire

NeurAxis Announces Positive University of Michigan IB-Stim™ Cost Effectiveness Study at ANMS 2023

CARMEL, Ind., Aug. 15, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address ...

10 months ago - GlobeNewsWire